Pamela Ross, NP
Nurse Practitioner · Fairfax, VANPI 1134803315
Payments from drug & device makers
Across 89 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$335
- Incyte Corporation$186
- AstraZeneca$181
- Daiichi Sankyo Inc.$161
- Merck$145
- Novartis$126
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,22190%
- Education$25910%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 12 | $335 |
| Incyte Corporation | 5 | $186 |
| AstraZeneca(2 entities) | 5 | $181 |
| Daiichi Sankyo Inc. | 3 | $161 |
| Merck | 6 | $145 |
| Novartis | 5 | $126 |
| Exelixis Inc. | 3 | $107 |
| Pharmaessentia USA Corporation | 3 | $91 |
| Tempus AI, Inc | 2 | $71 |
| AVEO Pharmaceuticals, Inc. | 2 | $71 |
| Bristol Myers Squibb | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Sanofi | 3 | $63 |
| AbbVie | 2 | $62 |
| Bayer | 2 | $58 |
| Seagen Inc. | 2 | $53 |
| Genentech USA, Inc. | 2 | $48 |
| EMD Serono, Inc. | 1 | $38 |
| GSK | 1 | $34 |
| Mirati Therapeutics, Inc. | 1 | $34 |
| Ipsen Biopharmaceuticals, Inc | 1 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $32 |
| Stemline Therapeutics Inc. | 1 | $28 |
| Acrotech Biopharma Inc. | 2 | $27 |
| Gilead | 1 | $25 |
| Mylan Institutional Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Springworks Therapeutics, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Secura Bio, Inc. | 1 | $18 |
| Deciphera Pharmaceuticals Inc. | 1 | $17 |
| Coherus Oncology, Inc. | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $14 |
How this compares
$2,480 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 13 | $270 |
| Acyclovir | 22 | $159 |
| Warfarin Sodium | 12 | $36 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Fairfax
- Pamela StenborgFairfax$8K
- Wendy HoltFairfax$7K
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.